View all newsletters
Receive our newsletter - data, insights and analysis delivered to you

FDA authorises Moderna to conduct Phase II trial of Covid-19 vaccine

The U Food and Drug Administration (FDA) has completed its review of Moderna’s investigational new drug (IND) application for Covid-19 vaccine candidate, mRNA-1273,  authorising the company to conduct a Phase II study.

The protocol for Phase III study of mRNA-1273 has also been finalised. While the Phase II clinical trial is set to begin soon, the Phase III study will be conducted later this year.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena